Obicetrapib在高心血管风险患者中对脂蛋白(a)水平的影响:汇总分析
该汇总分析纳入2356例高心血管风险患者(82%有ASCVD史,27%为HeFH,91%使用他汀),评估每日10mg obicetrapib与安慰剂相比12周的血脂效应。结果显示,obicetrapib使LDL-C降低37.0%、apoB降低21.3%、Lp(a)降低37.3%,在基线Lp(a)≥50-<150 nmol/L者中Lp(a)降低43.3%,且Lp(a)绝对降低在基线≥50-<150与≥150 nmol/L两组相似。
要点
- obicetrapib 10mg每日一次12周可显著降低LDL-C、apoB和Lp(a)。
- 基线Lp(a)≥50-<150 nmol/L者Lp(a)百分比降低43.3%,绝对降低36.3 nmol/L。
- 基线Lp(a)≥150 nmol/L者Lp(a)绝对降低与轻度升高者相似。
核心结论
- obicetrapib降低LDL-C、apoB和Lp(a),且Lp(a)绝对降低在轻度升高与显著升高患者中相似。
研究设计与样本
- 汇总分析纳入2356例HeFH或ASCVD患者,比较每日obicetrapib 10mg与安慰剂12周的血脂效应。
- 汇总队列中位年龄66岁,36%为女性,82%有ASCVD史,27%为HeFH,91%使用他汀。
主要发现
- obicetrapib安慰剂校正后降低LDL-C 37.0%和35 mg/dL,降低apoB 21.3%和20 mg/dL,降低Lp(a) 37.3%和14.9 nmol/L。
- 基线Lp(a)≥50-<150 nmol/L者,obicetrapib安慰剂校正后Lp(a)降低43.3%和36.3 nmol/L。
- 基线Lp(a)≥150 nmol/L者Lp(a)百分比降低低于≥50-<150 nmol/L者,但绝对降低相似(-32.3 vs -36.3 nmol/L)。
临床怎么用
- obicetrapib可作为高心血管风险患者综合降脂策略的一部分,同时降低LDL-C、apoB和Lp(a)。
- 对于Lp(a)轻度升高、可能不符合RNA靶向Lp(a)降低治疗条件的患者,obicetrapib可提供相似的Lp(a)绝对降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: There is interest in developing lipoprotein(a) [Lp(a)] lowering therapies. Cholesteryl ester transfer protein inhibitors lower Lp(a), however the effects of the selective inhibitor obicetrapib on Lp(a) levels in high cardiovascular risk patients have not been fully elucidated. This analysis investigated the effect of obicetrapib on Lp(a). METHODS: A pooled analysis of trials evaluating the 12-week lipid effects of daily obicetrapib 10 mg compared with placebo in patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) investigated the effect of obicetrapib on Lp(a) levels. RESULTS: In 2356 patients, the pooled cohort had a median age of 66 years, 36% were female with a history of ASCVD in 82%, HeFH in 27% and statin use in 91%. Median baseline lipid levels included low-density lipoprotein cholesterol (LDL-C) of 92 mg/dL, apolipoprotein B (apoB) of 87 mg/dL and Lp(a) of 42.9 nmol/L. Obicetrapib produced placebo-adjusted reductions in LDL-C of 37.0% and 35 mg/dL, in apoB of 21.3% and 20 mg/dL, and in Lp(a) of 37.3% and 14.9 nmol/L. In patients with baseline Lp(a) levels ≥50-<150 nmol/L, obicetrapib produced placebo-adjusted reductions in Lp(a) of 43.3% and 36.3 nmol/L. While patients with baseline Lp(a) ≥150 nmol/L demonstrated a lower percentage reduction in Lp(a) with obicetrapib than those with baseline levels ≥50-<150 nmol/L, the absolute reduction in Lp(a) was similar in both groups (-32.3 vs -36.3 nmol/L). CONCLUSIONS: Obicetrapib lowered LDL-C, apoB and Lp(a). The absolute reduction in Lp(a) with obicetrapib was similar in patients with mildly elevated Lp(a) levels, who are unlikely to qualify for administration of RNA-targeted Lp(a) lowering agents.
引用
- Nicholls SJ, Nelson AJ, Ray KK, et al. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. 2026. PMID: 42183881. doi:10.1093/eurheartj/ehag399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。